SynthesisBMC nutrition2026
Zinc supplementation in liver cirrhosis: meta-analysis of its effect on biochemical and clinical outcomes.
Synthesis in BMC nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Covert hepatic encephalopathy in cirrhosis: implications for early diagnosis and appropriate management.Clinical journal of gastroenterology · 2026Review
- Serum Zinc Threshold and the Prognostic Impact of Zinc Supplementation in Liver Cirrhosis.Nutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveZinc deficiency is common in patients with liver cirrhosis, and the effects of zinc supplementation on cirrhosis remain controversial. This study aims to explore the effectiveness of zinc supplementation in the clinical treatment of cirrhosis and hepatic encephalopathy.
methodsMEDLINE, Embase, Cochrane Library, Scopus, Ovid, and Web of Science databases were searched with a cutoff date of March 2025. A meta-analysis of randomized controlled trials on the efficacy of zinc supplementation in the treatment of liver cirrhosis and hepatic encephalopathy was performed using RevMan5.4 and StataMP17 software.
resultsSeven studies comprising 338 patients with cirrhosis (172 patients in the treatment group and 166 patients in the control group) were included. Results indicated that zinc supplementation slightly increased serum albumin levels compared with those of the control group (WMD=0.07, 95% CI [0.00, 0.14], P=0.04). In particular, zinc supplementation dose of <50 mg and time of ≥16 weeks showed a slight advantage. Zinc supplementation also improved（alanine aminotransferase）ALT content (WMD=−8.83, 95% CI [−15.47, −2.19], P=0.009), reduced blood ammonia levels (WMD=−5.92, 95% CI [−10.52, −1.32], P=0.01), and shortened the NCT - A time (WMD = 7.31, 95% CI [-9.52, -5.09], P < 0.001).
conclusionZinc supplementation may modestly improve nutritional parameters, hepatic function, and reduce the risk of hepatic encephalopathy in patients with cirrhosis. However, some outcomes demonstrated limited clinical significance, and further research is needed to determine the optimal dosage and duration of zinc supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.